WO2001035979A3 - Combined pde3 and pde4 inhibitor therapy for the treatment of obesity - Google Patents

Combined pde3 and pde4 inhibitor therapy for the treatment of obesity Download PDF

Info

Publication number
WO2001035979A3
WO2001035979A3 PCT/US2000/042137 US0042137W WO0135979A3 WO 2001035979 A3 WO2001035979 A3 WO 2001035979A3 US 0042137 W US0042137 W US 0042137W WO 0135979 A3 WO0135979 A3 WO 0135979A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
treatment
pde4 inhibitor
inhibitor therapy
pde3
Prior art date
Application number
PCT/US2000/042137
Other languages
French (fr)
Other versions
WO2001035979A2 (en
Inventor
Peter Snyder
Original Assignee
Icos Corp
Peter Snyder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp, Peter Snyder filed Critical Icos Corp
Priority to AU32703/01A priority Critical patent/AU3270301A/en
Publication of WO2001035979A2 publication Critical patent/WO2001035979A2/en
Publication of WO2001035979A3 publication Critical patent/WO2001035979A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides materials and methods for the treatment of obesity that involve a combination of a PDE3 and PDE4 inhibitor in synergistically effective amounts.
PCT/US2000/042137 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity WO2001035979A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32703/01A AU3270301A (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16541899P 1999-11-13 1999-11-13
US60/165,418 1999-11-13

Publications (2)

Publication Number Publication Date
WO2001035979A2 WO2001035979A2 (en) 2001-05-25
WO2001035979A3 true WO2001035979A3 (en) 2002-01-03

Family

ID=22598815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042137 WO2001035979A2 (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU3270301A (en)
WO (1) WO2001035979A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
AU2002312543A1 (en) * 2001-08-01 2003-02-17 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
FR2849594B1 (en) * 2003-01-03 2006-10-27 Oreal USE OF ZARDAVERINE AS SLIMMING
JP2007504201A (en) 2003-09-05 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト Use of PDE4 inhibitors for the treatment of diabetes mellitus
US8017633B2 (en) 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US20100179131A1 (en) * 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
JPWO2009154230A1 (en) * 2008-06-17 2011-12-01 持田製薬株式会社 Non-alcoholic steatohepatitis prevention / improvement / treatment drug
JP5842254B2 (en) * 2010-06-23 2016-01-13 国立大学法人九州大学 Combination of EGCG or methylated EGCG and PDE inhibitor
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
CA3026083C (en) * 2016-06-03 2024-04-02 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOUSA M K ET AL: "Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection?.", CLINICAL NEPHROLOGY, (1997 MAR) 47 (3) 187-9., XP002168562 *
PAN X ET AL: "Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.", BIOCHEMICAL PHARMACOLOGY, (1994 AUG 17) 48 (4) 827-35., XP002168561 *
SCHMITZ-PEIFFER C ET AL: "Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells.", CELLULAR SIGNALLING, (1992 JAN) 4 (1) 37-49., XP002168563 *

Also Published As

Publication number Publication date
AU3270301A (en) 2001-05-30
WO2001035979A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2000038786A3 (en) Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
HK1062518A1 (en) Materials and methods for the treatment or prevention of obesity
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
WO2002098416A3 (en) Antineoplastic combinations
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU2002364171A8 (en) Materials and methods for the treatment or prevention of obesity
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
AU2002247973A1 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
PL375631A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase